NCT03446274View on ClinicalTrials.gov

An Open Label, Single-Dose Study of 14C-NW-3509 in Healthy Male Subjects

PHASE1UnknownINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 2, 2018

Primary Completion Date

April 23, 2018

Study Completion Date

June 30, 2018

Conditions
Healthy
Interventions
DRUG

Evenamide

This is an orally available small molecule that potently blocks voltage-gated sodium channels (VGSCs) in vitro and is indicated for the treatment of patients with schizophrenia, mania, and bipolar disorder.

Trial Locations (1)

Unknown

RECRUITING

Quotient Sciences, Nottingham

Sponsors
All Listed Sponsors
lead

Newron Pharmaceuticals SPA

INDUSTRY

NCT03446274 - An Open Label, Single-Dose Study of 14C-NW-3509 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter